{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-137861","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.949843+00:00","generated_at":"2026-05-15T08:00:13.726346+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Design Therapeutics appoints Dr. David Shapiro to Board as Class III director","bullets":["Dr. David Shapiro appointed to Board effective Mar 31, 2026, as Class III director with term through 2027 annual meeting.","Receives annual cash retainer of $40k for Board service and $5k for Nominating Committee service.","Received initial option grant of 60k shares (3-year monthly vest) and prorated annual option of 7.5k shares (1-year vest).","Also appointed to the Nominating and Corporate Governance Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-137861","json":"https://secwatch.observer/filing/0001193125-26-137861.json","markdown":"https://secwatch.observer/filing/0001193125-26-137861.md","text":"https://secwatch.observer/filing/0001193125-26-137861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526137861/0001193125-26-137861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526137861/dsgn-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:00:13.726346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}